INSULIN,GLARGINE,HUMAN (TOUJEO) 300 UNIT/ ML
Clinical Criteria Summary
Exclusion Criteria
- Hypersensitivity to insulin glargine or glargine biosimilar
Inclusion Criteria
- Patient is insulin resistant (requires >1 unit/kg/day)
- Patient with recurrent episodes of hypoglycemia on insulin glargine 100 u/mL (e.g., > three Level 2 or one Level 3 hypoglycemic event within a one-month period) despite use of continuous glucose monitor (CGM) and adjustments made to current insulin regimen
Dosing & Device Considerations
- TOUJEO MAX is preferred in patients with insulin resistance receiving high doses of insulin
- TOUJEO MAX delivers in 2-unit increments and can deliver up to 160 units in a single injection
Additional Clinical Requirements
- Clinical need for concentrated, smaller volume insulin injections must be demonstrated
- Patients doing well on glargine 100 u/mL should not be switched to concentrated insulin solely for the purpose of achieving smaller volume injections
- Consider insulin sensitizing agents (metformin, empagliflozin, or semaglutide) unless contraindicated if not already receiving